Protein prune homolog 2 (PRUNE2)

Homo sapiens — UniProt Q8WUY3

Gene: PRUNE2Homo sapiensSwissProt reviewed

Data last refreshed: 2026-04-18 (UniProt release unknown)

Key facts

Protein prune homolog 2 (PRUNE2) is a protein from Homo sapiens identified by UniProt accession Q8WUY3, 3088 residues long. MolForge cross-references it against 0 known binders and 103 disease associations.

UniProt accession: Q8WUY3; gene symbol PRUNE2.
Organism: Homo sapiens.
Length: 3088 amino acids.
Top disease associations (Open Targets): neutrophil count, leukocyte count and dentures.
3D structure: AlphaFold model available.

Target properties

Protein name	Protein prune homolog 2
UniProt accession	Q8WUY3
Gene	PRUNE2
Organism	Homo sapiens
Length	3088 residues
Molecular weight	—
EC numbers	—
Target class	—
Subcellular location	—
Keywords	—

Druggability

Target tractability assessment (Open Targets + pocket analysis). No approved drug

Druggability tier	MEDIUM
Druggability score	—
Pocket score	—
Max clinical phase	—

Disease associations (103)

Diseases linked to this target (Open Targets).

neutrophil count · score 0.47
leukocyte count · score 0.43
dentures · score 0.40
myeloid white cell count · score 0.40
platelet component distribution width · score 0.34
dental caries · score 0.32
aspartate aminotransferase to alanine aminotransferase ratio · score 0.31
glucuronate measurement · score 0.27
metabolite measurement · score 0.26
neoplasm · score 0.09

3D Structure (10)

Experimental (PDB) and predicted (AlphaFold) structures for this protein.

Structure	Source	Method	Mean pLDDT	Resolution (Å)
AF-Q8WUY3-F1	alphafold	PREDICTED	45.48	—
AF-Q8WUY3-F10	alphafold	PREDICTED	43.38	—
AF-Q8WUY3-F9	alphafold	PREDICTED	39.73	—
AF-Q8WUY3-F2	alphafold	PREDICTED	39.10	—
AF-Q8WUY3-F3	alphafold	PREDICTED	36.74	—
AF-Q8WUY3-F7	alphafold	PREDICTED	36.60	—
AF-Q8WUY3-F6	alphafold	PREDICTED	36.50	—
AF-Q8WUY3-F8	alphafold	PREDICTED	36.44	—

Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q8WUY3.

Amino-acid sequence (3088 residues)

MEEFLQRAKS KLNRSKRLEK VHVVIGPKSC DLDSLISTFT YAYFLDKVSP PGVLCLPVLN IPRTEFNYFT ETRFILEELN ISESFHIFRD EINLHQLNDE GKLSITLVGS SVLASEDKTL ESAVVKVINP VEQSDANVEF RESSSSLVLK EILQEAPELI TEQLAHRLRG SILFKWMTME SEKISEKQEE ILSILEEKFP NLPPREDIIN VLQETQFSAQ GLSIEQTMLK DLKELSDGEI KVAISTVSMN LENCLFHSNI TSDLKAFTDK FGFDVLILFS SYLSEEQQPR RQIAVYSENM ELCSQICCEL EECQNPCLEL EPFDCGCDEI LVYQQEDPSV TCDQVVLVVK EVINRRCPEM VSNSRTSSTE AVAGSAPLSQ GSSGIMELYG SDIEPQPSSV NFIENPPDLN DSNQAQVDAN VDLVSPDSGL ATIRSSRSSK ESSVFLSDDS PVGEGAGPHH TLLPGLDSYS PIPEGAVAEE HAWSGEHGEH FDLFNFDPAP MASGQSQQSS HSADYSPADD FFPNSDLSEG QLPAGPEGLD GMGTNMSNYS SSSLLSGAGK DSLVEHDEEF VQRQDSPRDN SERNLSLTDF VGDESPSPER LKNTGKRIPP TPMNSLVESS PSTEEPASLY TEDMTQKATD TGHMGPPQTH ARCSSWWGGL EIDSKNIADA WSSSEQESVF QSPESWKEHK PSSIDRRASD SVFQPKSLEF TKSGPWESEF GQPELGSNDI QDKNEESLPF QNLPMEKSPL PNTSPQGTNH LIEDFASLWH SGRSPTAMPE PWGNPTDDGE PAAVAPFPAW SAFGKEDHDE ALKNTWNLHP TSSKTPSVRD PNEWAMAKSG FAFSSSELLD NSPSEINNEA APEIWGKKNN DSRDHIFAPG NPSSDLDHTW TNSKPPKEDQ NGLVDPKTRG KVYEKVDSWN LFEENMKKGG SDVLVPWEDS FLSYKCSDYS ASNLGEDSVP SPLDTNYSTS DSYTSPTFAG DEKETEHKPF AKEEGFESKD GNSTAEETDI PPQSLQQSSR NRISSGPGNL DMWASPHTDN SSEINTTHNL DENELKTEHT DGKNISMEDD VGESSQSSYD DPSMMQLYNE TNRQLTLLHS STNSRQTAPD SLDLWNRVIL EDTQSTATIS DMDNDLDWDD CSGGAAIPSD GQTEGYMAEG SEPETRFTVR QLEPWGLEYQ EANQVDWELP ASDEHTKDSA PSEHHTLNEK SGQLIANSIW DSVMRDKDMS SFMLPGSSHI TDSEQRELPP EIPSHSANVK DTHSPDAPAA SGTSESEALI SHLDKQDTER ETLQSDAASL ATRLENPGYF PHPDPWKGHG DGQSESEKEA QGATDRGHLD EEEVIASGVE NASGISEKGQ SDQELSSLVA SEHQEICIKS GKISSLAVTF SPQTEEPEEV LEYEEGSYNL DSRDVQTGMS ADNLQPKDTH EKHLMSQRNS GETTETSDGM NFTKYVSVPE KDLEKTEECN FLEPENVGGG PPHRVPRSLD FGDVPIDSDV HVSSTCSEIT KNLDVKGSEN SLPGAGSSGN FDRDTISSEY THSSASSPEL NDSSVALSSW GQQPSSGYQE ENQGNWSEQN HQESELITTD GQVEIVTKVK DLEKNRINEF EKSFDRKTPT FLEIWNDSVD GDSFSSLSSP ETGKYSEHSG THQESNLIAS YQEKNEHDIS ATVQPEDARV ISTSSGSDDD SVGGEESIEE EIQVANCHVA EDESRAWDSL NESNKFLVTA DPKSENIYDY LDSSEPAENE NKSNPFCDNQ QSSPDPWTFS PLTETEMQIT AVEKEKRSSP ETGTTGDVAW QISPKASFPK NEDNSQLEML GFSADSTEWW KASPQEGRLI ESPFERELSD SSGVLEINSS VHQNASPWGV PVQGDIEPVE THYTNPFSDN HQSPFLEGNG KNSHEQLWNI QPRQPDPDAD KFSQLVKLDQ IKEKDSREQT FVSAAGDELT PETPTQEQCQ DTMLPVCDHP DTAFTHAEEN SCVTSNVSTN EGQETNQWEQ EKSYLGEMTN SSIATENFPA VSSPTQLIMK PGSEWDGSTP SEDSRGTFVP DILHGNFQEG GQLASAAPDL WIDAKKPFSL KADGENPDIL THCEHDSNSQ ASDSPDICHD SEAKQETEKH LSACMGPEVE SSELCLTEPE IDEEPIYEPG REFVPSNAEL DSENATVLPP IGYQADIKGS SQPASHKGSP EPSEINGDNS TGLQVSEKGA SPDMAPILEP VDRRIPRIEN VATSIFVTHQ EPTPEGDGSW ISDSFSPESQ PGARALFDGD PHLSTENPAL VPDALLASDT CLDISEAAFD HSFSDASGLN TSTGTIDDMS KLTLSEGHPE TPVDGDLGKQ DICSSEASWG DFEYDVMGQN IDEDLLREPE HFLYGGDPPL EEDSLKQSLA PYTPPFDLSY LTEPAQSAET IEEAGSPEDE SLGCRAAEIV LSALPDRRSE GNQAETKNRL PGSQLAVLHI REDPESVYLP VGAGSNILSP SNVDWEVETD NSDLPAGGDI GPPNGASKEI SELEEEKTIP TKEPEQIKSE YKEERCTEKN EDRHALHMDY ILVNREENSH SKPETCEERE SIAELELYVG SKETGLQGTQ LASFPDTCQP ASLNERKGLS AEKMSSKSDT RSSFESPAQD QSWMFLGHSE VGDPSLDARD SGPGWSGKTV EPFSELGLGE GPQLQILEEM KPLESLALEE ASGPVSQSQK SKSRGRAGPD AVTLQAVTHD NEWEMLSPQP VQKNMIPDTE MEEETEFLEL GTRISRPNGL LSEDVGMDIP FEEGVLSPSA ADMRPEPPNS LDLNDTHPRR IKLTAPNINL SLDQSEGSIL SDDNLDSPDE IDINVDELDT PDEADSFEYT GHDPTANKDS GQESESIPEY TAEEEREDNR LWRTVVIGEQ EQRIDMKVIE PYRRVISHGG YYGDGLNAII VFAACFLPDS SRADYHYVME NLFLYVISTL ELMVAEDYMI VYLNGATPRR RMPGLGWMKK CYQMIDRRLR KNLKSFIIVH PSWFIRTILA VTRPFISSKF SSKIKYVNSL SELSGLIPMD CIHIPESIIK LDEELREASE AAKTSCLYND PEMSSMEKDI DLKLKEKP

External references

UniProt AlphaFold QuickGO RCSB PDB GeneCards

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

Which diseases are associated with PRUNE2?

The strongest Open Targets associations for PRUNE2 are neutrophil count, leukocyte count, dentures, myeloid white cell count and platelet component distribution width.

How long is the PRUNE2 protein?

The Homo sapiens PRUNE2 protein (UniProt Q8WUY3) is 3088 amino acids long.

Browse: Targets: P · all protein targets A–Z · drugs A–Z.

Sources

UniProtKB Q8WUY3 — name, gene, function, sequence, keywords (CC BY 4.0)
AlphaFold DB Q8WUY3 — predicted 3D structure (CC BY 4.0)
Open Targets Platform — disease associations and tractability (CC0)

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.